In this study, we evaluate the effect of HO-1 upregulation on blood pressure and cardiac function in the new model of infarct spontaneous hypertensive rats (ISHR). Male spontaneous hypertensive rats (SHR) at 13 weeks (n = 40) and age-matched male Wistar (WT) rats (n = 20) were divided into six groups: WT (sham + normal saline (NS)), WT (sham + Co(III) Protoporphyrin IX Chloride (CoPP)), SHR (myocardial infarction (MI) + NS), SHR (MI + CoPP), SHR (MI + CoPP + Tin Mesoporphyrin IX Dichloride (SnMP)), SHR (sham + NS); CoPP 4.5 mg/kg, SnMP 15 mg/kg, for six weeks, one/week, i.p., n = 10/group. At the sixth week, echocardiography (UCG) and hemodynamics were performed. Then, blood samples and heart tissue were collected. Copp treatment in the SHR (MI + CoPP) group lowered blood pressure, decreased infarcted area, restored cardiac function (left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), +dp/dt_max, (−dp/dt_max)/left ventricular systolic pressure (LVSP)), inhibited cardiac hypertrophy and ventricular enlargement (downregulating left ventricular end-systolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and heart weight/body weight (HW/BW)), lowered serum CRP, IL-6 and Glu levels and increased serum TB, NO and PGI2 levels. Western blot and immunohistochemistry showed that HO-1 expression was elevated in the SHR (MI + CoPP) group, while co-administration with SnMP suppressed the benefit functions mentioned above. In conclusion, HO-1 upregulation can lower blood pressure and improve post-infarct cardiac function in the ISHR model. These functions may be involved in the inhibition of inflammation and the ventricular remodeling process and in the amelioration of glucose metabolism and endothelial dysfunction.

Background: The prevalence of chronic coronary heart diseases (CHDs) increases with age in the elderly, which represents one of the top-ranked causes of death and disease burden. Methods: This study aimed to investigate the management efficiency of telemedicine based on the remote multiparameter monitoring in elderly patients with CHD. A total of 1248 elderly patients diagnosed with CHD were enrolled. The subjects were randomly divided into two groups, wearable equipment-based telemedical management (WTM) group and traditional follow-up management (TFM) group. Face-to-face clinical interview at least once every 2 months was required in TFM group to collect the medical records. Patients in WTM group were provided with wearable equipment to complete remote monitoring, real-time alerts and health intervention via virtual consultations and remote medication recommendations. Results: The mean age of patients in WTM group and TFM group was 71.1 (68.0–82.0) years and 71.0 (68.0–81.0) years, respectively‏. After a 12-month management, patients in WTM group presented a lower occurrence of hospitalisation (HR 0.59, 95% CI=0.47 to 0.73, p<0.0001) and major adverse cardiac events (HR 0.60, 95% CI=0.44 to 0.82, p=0.0012) compared with patients in TFM group. Conclusion: The multiparameter telemedical management could help with the out-of-hospital management and reduce the incidence of rehospitalisation in elderly patients with CHD.